Apollo Therapeutics

About:

Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating medical research into medicines.

Website: http://apollotherapeutics.com

Top Investors: M&G Plc, Rock Springs Capital, Patient Square Capital, UCLB, Reimagined Ventures

Description:

Apollo Therapeutics is a collaborative venture between three UK universities (Imperial College London, University College London, and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best British academic research, accelerating them towards the clinic. Apollo’s unique model provides quick, independent access to the resources to grow innovations and champion the best British academic research to industry. Apollo’s experienced team of industry scientists has a proven track record of therapeutic delivery and works in partnership with academics and industry partners, crafting each bespoke project to optimize the chances of long-term success. Apollo Therapeutics aims to create future therapies by partnering with the UK’s globally leading academic science base and UK-based Pharma industry to have a real impact on patient treatments and outcomes.

Total Funding Amount:

$398M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2016-01-01

Contact Email:

info(AT)apollotx.com

Founders:

Ian Tomlinson

Number of Employees:

11-50

Last Funding Date:

2024-01-02

IPO Status:

Private

© 2025 bioDAO.ai